Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.
about
Diagnostic and prognostic biomarkers in melanoma.Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma.Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis.Metastatic melanoma - a review of current and future drugsProtein and non-protein biomarkers in melanoma: a critical update.Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
P2860
Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Use of S-100B to evaluate ther ...... nt in AJCC stage III melanoma.
@ast
Use of S-100B to evaluate ther ...... nt in AJCC stage III melanoma.
@en
type
label
Use of S-100B to evaluate ther ...... nt in AJCC stage III melanoma.
@ast
Use of S-100B to evaluate ther ...... nt in AJCC stage III melanoma.
@en
prefLabel
Use of S-100B to evaluate ther ...... nt in AJCC stage III melanoma.
@ast
Use of S-100B to evaluate ther ...... nt in AJCC stage III melanoma.
@en
P2093
P2860
P1476
Use of S-100B to evaluate ther ...... nt in AJCC stage III melanoma.
@en
P2093
A H Brouwers
A J H Suurmeijer
E Bastiaannet
G A Hospers
H J Hoekstra
M J Speijers
W B Nagengast
P2860
P2888
P304
P356
10.1245/S10434-011-2027-2
P577
2011-08-23T00:00:00Z
P5875
P6179
1001969109